Zhejiang Starry Pharm Co Ltd

Sitali released its 2026 interim report. The company's total operating revenue was 1.414 billion yuan, and net profit attributable to the parent company was 39.929 million yuan, ranking 98th among peer companies that have already disclosed results. Net cash inflow from operating activities was 111 million yuan, a decrease of 16.1285 million yuan, or 12.74%, compared with the same period last year. The company's latest asset-liability ratio was 58.59%, up 3.04 percentage points from the same period last year. Gross margin was 20.13%, down 2.12 percentage points from the previous quarter. ROE was 1.61%, and diluted earnings per share was 0.09 yuan. The number of shareholders was 52,200, and the top ten shareholders held 25.68% of the total share capital.

Star Lake released its 2026 interim report. In the first half, operating revenue was 1.41 billion yuan, up 1.2% year on year. Net profit attributable to the parent was 39.93 million yuan, up 37.1% year on year, but non-recurring net profit attributable to the parent was 14.04 million yuan, down 48.5% year on year. In the second quarter, operating revenue was 703 million yuan, down 1.2% year on year. Net profit attributable to the parent was 18.98 million yuan, up 28.3% year on year, while non-recurring net profit attributable to the parent was a loss of 2.82 million yuan, down 117.5% year on year. As of the end of the second quarter, total assets were 5.997 billion yuan, down 2.6% from the end of the previous year, and net assets attributable to the parent were 2.477 billion yuan, down 3.2%. The company said its active pharmaceutical ingredient business continued to grow, but sales of some products were constrained by production capacity. The intermediate business was adjusted flexibly, and the formulation business advanced its integration strategy. During the reporting period, the company completed the sale of equity in an associate and recognized investment income, which is expected to have a certain impact on operations but does not involve adjustments to its main business. Demand in the iodine contrast agent market is steadily rising, providing a foundation for sustainable improvement in future performance.

Sitaili announced that controlling shareholders Hu Jian and Hu Jinsheng have pledged a combined 24.65 million shares, accounting for 27.09% of their total holdings and 5.62% of the company's total share capital. Among them, Hu Jian has cumulatively pledged 7.75 million shares, representing 16.74% of his holdings and 1.77% of the company's total share capital; Hu Jinsheng has cumulatively pledged 34.9 million shares, representing 78.12% of his holdings and 7.96% of the company's total share capital. In the first quarter of 2026, the company achieved revenue of 711 million yuan and a net profit attributable to the parent company of 20.95 million yuan.